Clinical Renal Associates Ltd.

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Obesity3 trials
• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Peripheral artery disease1 trial
• Stroke1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting1 trial
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

  Contact: Heather Mascio (principal investigator)

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Heather Mascio (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes1 recruiting